|
melanoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We have reported the identification of human gene MAGE-1, which directs the expression of an antigen recognized on a melanoma by autologous cytolytic T lymphocytes (CTL).
|
1402688 |
1992 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Antigen MZ2-E appears to be presented by HLA-A1; anti-MZ2-E CTLs of the original patient recognized two melanoma cell lines of other HLA-A1 patients that expressed the gene.
|
1840703 |
1991 |
|
melanoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
5-Aza-2'-deoxycytidine (DAC), a demethylating agent, was capable of inducing MAGE-1 expression by a MAGE-1-negative melanoma cell line 888-mel as well as by a number of other melanoma cell lines.
|
7511051 |
1994 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We have produced a MAGE-1-specific CTL line derived from the tumor-infiltrating lymphocytes (TIL) of a melanoma patient by weekly restimulation with autologous EBV-B cells pulsed with the synthetic HLA-A1-restricted MAGE-1 epitope nonapeptide EADPTGHSY.
|
7519125 |
1994 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Autologous cytolytic T lymphocytes recognize a MAGE-1 nonapeptide on melanomas expressing HLA-Cw*1601.
|
7522162 |
1994 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The genes MAGE-1 and MAGE-3 both encode melanoma peptide antigens recognized by major histocompatibility complex-restricted cytotoxic T lymphocytes.
|
7557134 |
1995 |
|
melanoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The human genes MAGE-1 and -3 encode melanoma peptide antigens that are recognized by autologous cytotoxic T lymphocytes.
|
7591261 |
1995 |
|
melanoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
These results suggest that this type of autologous ex vivo cultured population of professional APC, when pulsed with the relevant-CTL-determined peptide, can serve as a novel type of candidate vaccine for active specific immunization against HLA-A1-positive patients with melanoma expressing the MAGE-1 antigen.
|
7750125 |
1995 |
|
melanoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Serological typing of normal and tumor cell lysates was in full agreement with mRNA analysis, showing expression of MAGE-1 protein in MAGE-1 mRNA-positive testis and a subset of melanomas but not in MAGE-1 mRNA-negative normal or tumor tissues.
|
8302824 |
1994 |
|
melanoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
MAGE-1 is not likely to be the common melanoma antigen recognized by the other HLA-A1- or HLA-A2-restricted cytotoxic T-lymphocytes examined in this study, but the fact that it is expressed in about 50% of melanoma cell lines makes it a reasonable target for the immunotherapy of patients bearing HLA-A1.
|
8416750 |
1993 |
|
melanoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Gene MAGE-1 is expressed in approximately 40% of melanoma tumor samples and by some tumors of other histological types.
|
8513199 |
1993 |
|
melanoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
It has previously been reported that MAGE-1, -2, -3 and -4 genes are expressed in human cancers including cutaneous melanoma.
|
8647642 |
1996 |
|
melanoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The MAGE-1 and MAGE-3 genes are expressed in tumors of different histotypes but not in normal adult tissues (with the exception of testis), while the MART-1 gene appears to be selectively expressed in melanoma.
|
8900375 |
1996 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Immunohistology is thus a rapid and well-established method that might be used to select and monitor HLA-A1 positive patients with malignant melanoma and other candidate tumours for MAGE-1-directed immuno-therapy.
|
8917707 |
1996 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
These results suggest a pattern of TCR conservation in CTL selected for recognition of MAGE-1 or BAGE peptides on the autoiogous melanoma.
|
8921424 |
1996 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Incubation of transduced HLA-A1 expressing melanoma cell lines with 2 anti-MAGE-1.A1 CTL clones resulted in specific recognition and lysis of target cells, indicating that the exogenous MAGE-1 protein was processed and presented in a normal manner.
|
9378539 |
1997 |
|
melanoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
To identify new CT antigens, we constructed an expression cDNA library from a melanoma cell line that expresses a wide range of CT antigens and screened the library with an allogeneic melanoma patient serum known to contain antibodies against two CT antigens, MAGE-1 and NY-ESO-1. cDNA clones isolated from this library identified four CT antigen genes: MAGE-4a, NY-ESO-1, LAGE-1, and CT7.
|
9618514 |
1998 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
PCR-based analysis of the freshly harvested tumor from patient PM2-B2 revealed the presence of message for the melanoma-associated gene products MAGE-1 and MAGE-3, but not for tyrosinase or MART-1/MELAN-A.
|
9816095 |
1996 |
|
melanoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Knowledge of these mechanisms led to the design of a non-natural, minimally modified analogue of MAGE-1.A1, [Aib2, NMe-Ser8]MAGE-1.A1, which was highly peptidase-resistant and bound to MHC and activated MAGE-1.A1-specific anti-melanoma CTLs.
|
10187808 |
1999 |
|
melanoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
MAGE 1 and 3 gene expression was also not detected in any of the cases of benign and dysplastic melanocytic naevi and in situ MMs.
|
10215777 |
1999 |
|
melanoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Expression of MAGE-10 in melanoma tumors was found to parallel that of MAGE-1.
|
10446460 |
1999 |
|
melanoma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
Transcription of the MAGE-1 gene and the methylation status of its Ets binding promoter elements: a quantitative analysis in melanoma cell lines using a real-time polymerase chain reaction technique.
|
10465576 |
1999 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Peptide sequences from MAGE-1, 2, 3, 4a, and 6 aligned to MAGE-12:170-178 were not recognized by F001-TIL.
|
10754339 |
2000 |
|
melanoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Using several different preexisting tumor models that make use of B16F10 melanoma cells expressing a target tumor antigen (human melanoma-associated gene [MAGE]-1), we found that vaccination with bone marrow-derived DCs engineered to express MAGE-1 via adenoviral-mediated gene transfer led to a dramatic decrease in the number of metastases in a lung metastasis model, and led to prolonged survival and some long-term cures in a subcutaneous preexisting tumor model.
|
10811863 |
2000 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Subsequently, we chose four sets of primers for the melanoma-associated antigens MAGE1, tyrosinase, Melan A/MART-1 and gp100/Pmel17 and performed PCR analysis over a range of cycle numbers.
|
11604998 |
2001 |